✦ LIBER ✦

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

✍ Scribed by Mario H. Cardiel; James A. Tumlin; Richard A. Furie; Daniel J. Wallace; Tenshang Joh; Matthew D. Linnik

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 324 KB
Volume: 58
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23673

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

LJP 394 for the prevention of renal flar

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study

✍ Donato Alarcón-Segovia; James A. Tumlin; Richard A. Furie; James D. McKay; Mario 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

## Abstract ## Objective To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. ## Methods In a 76‐week, double‐blind, placebo‐controlled study, 230 SLE patients were randomized to receive 16 weekly doses of

Efficacy and safety of rituximab in mode

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

✍ Joan T. Merrill; C. Michael Neuwelt; Daniel J. Wallace; Joseph C. Shanahan; Kevi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p

The efficacy and safety of abatacept in

The efficacy and safety of abatacept in patients with non–life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

✍ J. T. Merrill; R. Burgos-Vargas; R. Westhovens; A. Chalmers; D. D'Cruz; D. J. Wa 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 2 views

The effect of moderate-dose corticostero

The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial

✍ Chung-E Tseng; Jill P. Buyon; Mimi Kim; H. Michael Belmont; Meggan Mackay; Betty 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## Objective Serial measurements of anti–double‐stranded DNA (anti‐dsDNA) and complement are routine in the management of systemic lupus erythematosus (SLE), but their utility as biomarkers in preemptive treatment to prevent flares remains a subject of controversy. We hypothesized that

Reduced B lymphocyte and immunoglobulin

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial

✍ Maria Dall'Era; Eliza Chakravarty; Daniel Wallace; Mark Genovese; Michael Weisma 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 2 views